Akero Therapeutics Inc. (AKRO) and Jaguar Health Inc. (NASDAQ:JAGX) Comparison side by side

Both Akero Therapeutics Inc. (NASDAQ:AKRO) and Jaguar Health Inc. (NASDAQ:JAGX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akero Therapeutics Inc. 23 0.00 N/A -3.22 0.00
Jaguar Health Inc. 9 1.46 N/A -161.25 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Akero Therapeutics Inc. and Jaguar Health Inc.


Table 2 represents Akero Therapeutics Inc. (NASDAQ:AKRO) and Jaguar Health Inc. (NASDAQ:JAGX)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Akero Therapeutics Inc. 0.00% 0% 0%
Jaguar Health Inc. 0.00% -380.6% -79.9%


The current Quick Ratio of Akero Therapeutics Inc. is 29.4 while its Current Ratio is 29.4. Meanwhile, Jaguar Health Inc. has a Current Ratio of 0.3 while its Quick Ratio is 0.2. Akero Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Jaguar Health Inc.

Analyst Ratings

The Ratings and Recommendations for Akero Therapeutics Inc. and Jaguar Health Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Akero Therapeutics Inc. 0 0 0 0.00
Jaguar Health Inc. 0 0 1 3.00

Competitively the consensus target price of Jaguar Health Inc. is $5, which is potential 247.22% upside.

Institutional & Insider Ownership

Akero Therapeutics Inc. and Jaguar Health Inc. has shares owned by institutional investors as follows: 48.5% and 1.1%. Akero Therapeutics Inc.’s share owned by insiders are 17.8%. Insiders Comparatively, owned 13.23% of Jaguar Health Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Akero Therapeutics Inc. 5.86% 27.17% 0% 0% 0% 32.1%
Jaguar Health Inc. -2.27% -64.46% -88.75% -90.4% -97.61% -89.26%

For the past year Akero Therapeutics Inc. has 32.1% stronger performance while Jaguar Health Inc. has -89.26% weaker performance.


Akero Therapeutics Inc. beats Jaguar Health Inc. on 6 of the 8 factors.

Napo Pharmaceuticals, Inc., a human health company, focuses on developing and commercializing novel gastrointestinal prescription products from plants. Its products include Mytesi, an FDA approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Napo Pharmaceuticals, Inc. was formerly known as PS Pharmaceuticals, Inc. The company was founded in 2001 and is based in San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.